1. A booster dose of Delta × Omicron hybrid mRNA vaccine produced broadly neutralizing antibody against Omicron and other SARS-CoV-2 variants.
- Author
-
Lee, I-Jung, Sun, Cheng-Pu, Wu, Ping-Yi, Lan, Yu-Hua, Wang, I-Hsuan, Liu, Wen-Chun, Yuan, Joyce Pei-Yi, Chang, Yu-Wei, Tseng, Sheng-Che, Tsung, Szu-I, Chou, Yu-Chi, Kumari, Monika, Lin, Yin-Shiou, Chen, Hui-Feng, Chen, Tsung-Yen, Lin, Chih-Chao, Chiu, Chi-Wen, Hsieh, Chung-Hsuan, Chuang, Cheng-Ying, and Cheng, Chao-Min
- Subjects
- *
SARS-CoV-2 Omicron variant , *BOOSTER vaccines , *SARS-CoV-2 , *SARS-CoV-2 Delta variant , *VACCINES - Abstract
Background: With the continuous emergence of new SARS-CoV-2 variants that feature increased transmission and immune escape, there is an urgent demand for a better vaccine design that will provide broader neutralizing efficacy. Methods: We report an mRNA-based vaccine using an engineered "hybrid" receptor binding domain (RBD) that contains all 16 point-mutations shown in the currently prevailing Omicron and Delta variants. Results: A booster dose of hybrid vaccine in mice previously immunized with wild-type RBD vaccine induced high titers of broadly neutralizing antibodies against all tested SARS-CoV-2 variants of concern (VOCs). In naïve mice, hybrid vaccine generated strong Omicron-specific neutralizing antibodies as well as low but significant titers against other VOCs. Hybrid vaccine also elicited CD8+/IFN-γ+ T cell responses against a conserved T cell epitope present in wild type and all VOCs. Conclusions: These results demonstrate that inclusion of different antigenic mutations from various SARS-CoV-2 variants is a feasible approach to develop cross-protective vaccines. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF